Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Jan;48(1):340-3.
doi: 10.1128/AAC.48.1.340-343.2004.

In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis

Chiu-Yeung Chan  1 , Carrie Au-Yeang, Wing-Wai Yew, Chi-Chiu Leung, Augustine F B Cheng
Affiliations
Comparative Study

In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis

Chiu-Yeung Chan et al. Antimicrob Agents Chemother. 2004 Jan.

Abstract

Postantibiotic effects (PAEs) of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis ATCC 27294 were studied using a radiometric culture system. Rifapentine at 20 mg/liter gave the longest PAE (104 h) among the drugs used alone. The combinations of rifapentine plus isoniazid, rifapentine plus moxifloxacin, and isoniazid plus moxifloxacin gave PAEs of 136.5, 59.0, and 8.3 h, respectively.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
(A) Regrowth curves of M. tuberculosis H37Rv following 2 h of exposure to rifapentine (10 mg/liter). ○, cumulative GI of residual control; ♦, cumulative GI of exposed culture. The time interval between cumulative GI lines (arrows) denotes the PAE. (B) Regrowth curves of M. tuberculosis H37Rv following 2 h of exposure to isoniazid (2 mg/liter). ○, cumulative GI of residual control; ♦, cumulative GI of exposed culture. The time interval between the lines (arrows) denotes the PAE. (C) Regrowth curves of M. tuberculosis H37Rv following 2 h of exposure to moxifloxacin (2 mg/liter). ○, cumulative GI of residual control; ♦, cumulative GI of exposed culture. The time interval between the lines (arrows) denotes the PAE.
See this image and copyright information in PMC

References

    1. Benator, D., M. Bhattacharya, L. Bozeman, W. Burman, A. Cantazaro, R. Chaisson, F. Gordin, C. R. Horsburgh, J. Horton, A. Khan, C. Lahart, B. Metchock, C. Pachucki, L. Stanton, A. Vernon, M. E. Villarino, Y. C. Wang, M. Weiner, S. Weis, et al. 2002. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360:528-534. - PubMed
    1. Bock, N. N., T. R. Sterling, C. D. Hamilton, C. Pachucki, Y. C. Wang, D. S. Conwell, A. Mosher, M. Samuels, A. Vernon, et al. 2002. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am. J. Resp. Crit. Care Med. 165:1526-1530. - PubMed
    1. Bundtzen, R. W., A. U. Gerber, D. L. Cohn, and W. A. Craig. 1981. Post-antibiotic suppression of bacterial growth. Rev. Infect. Dis. 3:28-37. - PubMed
    1. Burkhardt, O., K. Borner, H. Stass, G. Beyer, M. Allewelt, C. E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand. J. Infect. Dis. 34:898-903. - PubMed
    1. Burman, W. J., K. Gallicano, and C. Peloquin. 2001. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341. - PubMed

Publication types

MeSH terms

LinkOut - more resources